Investors are bailing on CorMedix (NASDAQ: CRMD) today after the biotech firm guided for up to $320 million in revenue for its fiscal 2026.
The announcement isn’t sitting well with shareholders, primarily because CRMD’s topline was roughly $400 million in the prior year, according to the preliminary full-year financials it posted on Thursday.
Simply put, the NJ-headquartered firm expects its revenue to shrink this year, which seldom bodes well for investors. Following today’s plunge, CorMedix stock is down over 50% from its 52-week high.
CorMedix stock to remain subdued on DefenCath weakness
On July 1st, DefenCath will lose its temporary TDAPA reimbursement status and shift to a notably less favourable post-TDAPA add-on adjustment.
What this means is that dialysis providers will receive lower institutional reimbursement, and CorMedix will face materially reduced net pricing.
This will directly pressure its margins and undermine its near-term revenue visibility.
Note that “DefenCath” was CorMedix’s sole commercial product for a long time – and while the recent Melinta acquisition did expand its portfolio, those new revenue sources aren’t yet material enough to offset the expected weakness in its antimicrobial catheter lock solution.
This makes buying the dip in CRMD stock a rather risky proposition for serious investors.
CRMD shares’ technicals are just as concerning
CorMedix shares remain unattractive despite the sharp pullback, also because the management sees DefenCath sales sliding further to $140 million at the top end of its range in 2027.
Moreover, it’s not just fundamentals – the company’s technicals are just as concerning.
At the time of writing, CRMD is trading decisively below its major moving averages (MAs), indicating bears remain in control across multiple timeframes.
Plus, the biotech stock’s long-term relative strength index (100-day) sits at about “45” currently – which means the broader downtrend isn’t approaching exhaustion either.
Note that insiders have predominantly unloaded CorMedix in the trailing 12 months, reinforcing that those closest to the company believe it was overvalued at north of $10.
Taken together, these insights further strengthen the bear case for CRMD in 2026.
Is it worth investing in CorMedix today?
On Thursday, CorMedix also said its chief executive, Joseph Todisco, is taking over as chairman of the board as well.
This consolidation resides significant power in a single individual, reducing checks and balances that independent board oversight typically provides.
For investors, this dual role can be unsettling – as it heightens governance risk and may complicate accountability.
In the near term, this transition may mean uncertainty around strategic decision‑making, potentially undermining confidence in CRMD shares.
What’s also worth mentioning is that Wall Street had a consensus “buy” rating and $19 price target on CorMedix heading into 2026.
It’s reasonable to assume, however, that following the DefenCath update today, at least some firms will choose to downwardly revise their estimates for CRMD.
The post Why is CorMedix stock crashing today: is it worth buying on the dip? appeared first on Invezz
